New Research From Yale, Stress Triggers Tumor Formation
In a seminal finding in cancer research, Tian Xu, PhD and his colleagues have discovered that stress induces signals that cause cells to develop into tumors. Their discovery, published in the journal
, describes the JNK stress-signaling pathway, which is activated by environmental stress conditions making it easier for cancer to develop in the body. Tian is a Professor of Genetics and a member of the Cancer Genetics Research Program at Yale Cancer Center.
Cathy Lyons Named Director of Clinical Programs at Smilow Cancer Hospital
We are fortunate to have the expertise and experience of Cathy Lyons, RN as we continue to strengthen the clinical care and programs at Yale Cancer Center and Smilow Cancer Hospital at Yale-New Haven. Most recently Cathy was the Associate Director for Clinical Services at the James P. Wilmot Cancer Center at the University of Rochester and prior to that she served as Director of Nursing at Roswell Park Cancer Institute for 25 years. Cathy has already started making a positive impact here at Yale and we welcome her to our leadership team.
Melinda Irwin and Yong Zhu Selected to Lead Prevention and Control Research Program
The Yale Cancer Center Executive Committee recently approved the appointment of Melinda Irwin, PhD and Yong Zhu, PhD as Co-Directors of the Cancer Prevention and Control Research Program. Melinda's research concentrates on the relationship between physical activity and cancer prevention and survivorship. She is a principal investigator on two R01 grants from the National Cancer Institute. Yong's research focus is on the identification of biomarkers that can characterize inherited predisposition to cancers and cellular response to environmental factors.
Susan Mayne, PhD will remain as the Associate Director of Population Sciences for the Center and Ruth McCorkle, PhD will continue to serve as Assistant Director of Psychosocial Oncology. I am pleased that both Susan and Ruth will continue in their leadership positions for the Center and look forward to working with Melinda and Yong.
The integration of the 12 multidisciplinary cancer programs continues as we plan for collaborated care for all of our patients. Smilow Cancer Hospital recently added a Tumor Board Coordinator to the staff. Jeannette Brooks joined the hospital on Monday and will begin meeting with program leaders and attending tumor board conferences immediately as she formulates a critical gap analysis for the hospital.
Planning for the 7th floor occupancy continues, with clinical and support staff meeting with IT, facilities, and the entire Occupancy Committee to ensure a smooth transition for the hematology program in February.
Damon Runyon Cancer Research Foundation
Cancer Research Fund
The Damon Runyon Clinical Investigator Award supports young physician-scientists conducting patient-oriented cancer research. The goal is to increase the number of physicians capable of moving seamlessly between the laboratory and the patient's bedside in search of breakthrough treatments.
The $450,000 Award will be for a period of three years. Annually, funding of $150,000 ($100,000 stipend and $50,000 research allowance) will be allocated to the awardee's institution for the specific support of the Clinical Investigator.
Learn More >>
Newly Opened Clinical Trials
Principal Investigator: Francine Foss, MD HIC# 0909005750
A Multi-Center, Open Label Trial of Belinostat in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma
Interaction between Ras(V12) and scribbled clones induces tumour growth and invasion.
Wu M, Pastor-Pareja JC, Xu T.
Nature. 2010 Jan 13.
Read More >>
Aplidin as a potential adjunct to radiation therapy: in vitro studies.
Rockwell S, Liu Y.
Int J Radiat Biol. 2010 Jan;86(1):63-70.
Read More >>
Controversy surrounding the role for routine central lymph node dissection for differentiated thyroid cancer.
Carling T, Long WD 3rd, Udelsman R.
Curr Opin Oncol. 2010 Jan;22(1):30-4.
Read More >>
Prognosis for mammographically occult, early-stage breast cancer patients treated with breast-conservation therapy.
Yang TI, Yang Q, Haffty BG, Moran MS.
Int J Radiat Oncol Biol Phys. 2010 Jan 1;76(1):79-84.
Read More >>
Radiofrequency Ablation (RFA) of Pulmonary Metastases: Technical Success vs. Actual Benefit.